Free Trial

Bristol-Myers Squibb (BMY) Stock Forecast & Price Target

Bristol-Myers Squibb logo
$50.21 +0.99 (+2.01%)
As of 03:59 PM Eastern

Bristol-Myers Squibb - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
2
Hold
13
Buy
7

Based on 22 Wall Street analysts who have issued ratings for Bristol-Myers Squibb in the last 12 months, the stock has a consensus rating of "Hold." Out of the 22 analysts, 2 have given a sell rating, 13 have given a hold rating, 5 have given a buy rating, and 2 have given a strong buy rating for BMY.

Consensus Price Target

$58.00
15.51% Upside
According to the 22 analysts' twelve-month price targets for Bristol-Myers Squibb, the average price target is $58.00. The highest price target for BMY is $73.00, while the lowest price target for BMY is $39.00. The average price target represents a forecasted upside of 15.51% from the current price of $50.21.
Get the Latest News and Ratings for BMY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Bristol-Myers Squibb and its competitors.

Sign Up

BMY Analyst Ratings Over Time

TypeCurrent Forecast
4/30/24 to 4/30/25
1 Month Ago
3/31/24 to 3/31/25
3 Months Ago
1/31/24 to 1/30/25
1 Year Ago
5/1/23 to 4/30/24
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
Hold
13 Hold rating(s)
11 Hold rating(s)
13 Hold rating(s)
15 Hold rating(s)
Sell
2 Sell rating(s)
2 Sell rating(s)
2 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$58.00$57.86$56.60$60.00
Forecasted Upside15.51% Upside-5.23% Downside-4.24% Downside36.49% Upside
Consensus Rating
Hold
Hold
Hold
Hold

BMY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

BMY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Bristol-Myers Squibb Stock vs. The Competition

TypeBristol-Myers SquibbMedical CompaniesS&P 500
Consensus Rating Score
2.32
2.82
2.54
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside15.51% Upside3,228.63% Upside19.72% Upside
News Sentiment Rating
Positive News

See Recent BMY News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/25/2025Argus
3 of 5 stars
J. Hellweg
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold
4/25/2025William Blair
1 of 5 stars
 Reiterated RatingMarket Perform
4/23/2025Jefferies Financial Group
2 of 5 stars
Akash Tewari
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetBuy ➝ Buy$70.00 ➝ $68.00+36.49%
4/22/2025Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Carter Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$55.00 ➝ $55.00+12.36%
4/22/2025Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
David Amsellem
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$65.00+32.79%
4/11/2025UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Trung Huynh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral ➝ Neutral$60.00 ➝ $54.00+8.43%
4/8/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Asad Haider
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Neutral$67.00 ➝ $55.00+1.97%
2/7/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Mohit Bansal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetEqual Weight ➝ Equal Weight$60.00 ➝ $62.00+8.37%
1/28/2025Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Verdult
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetNeutral ➝ Neutral$60.00 ➝ $65.00+7.24%
1/8/2025Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$62.00 ➝ $65.00+13.60%
12/10/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$63.00+7.25%
11/15/2024Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Hammond
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoveragePeer Perform
11/13/2024Daiwa America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
N. Nakagiri
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/13/2024Daiwa Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeNeutral ➝ Outperform
11/12/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Risinger
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
11/12/2024BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform ➝ Market Perform$57.00 ➝ $61.00+2.09%
11/12/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetUnderweight ➝ Underweight$36.00 ➝ $39.00-34.80%
11/12/2024Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeMarket Perform ➝ Outperform$55.00 ➝ $73.00+22.03%
10/17/2024Sanford C. Bernstein
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Breen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageMarket Perform$56.00+4.93%
10/7/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Gould
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetUnderweight ➝ Underweight$42.00 ➝ $43.00-20.25%
10/7/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$53.00 ➝ $59.00+9.32%
7/23/2024Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHold ➝ Hold$53.00 ➝ $45.00+5.36%
3/11/2024Societe Generale
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
2/6/2024Redburn Atlantic
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral$77.00 ➝ $54.00+12.50%
10/27/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeReduce ➝ Hold$55.00 ➝ $53.00+0.03%
7/28/2023Atlantic Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$90.00 ➝ $85.00+39.89%
7/12/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$72.00 ➝ $66.00+5.13%
7/10/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$66.00+5.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 07:52 PM ET.


Should I Buy Bristol-Myers Squibb Stock? BMY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, April 24, 2025. Please send any questions or comments about these Bristol-Myers Squibb pros and cons to contact@marketbeat.com.

Bristol-Myers Squibb
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Bristol-Myers Squibb:

  • The current stock price is around $55, which may present a buying opportunity for investors looking for value in the pharmaceutical sector.
  • Bristol-Myers Squibb has a diverse portfolio of biopharmaceutical products, including recent advancements in treatments for various cancers and autoimmune diseases, which can drive future revenue growth.
  • The company has received positive ratings from several analysts, with a consensus target price of approximately $57.67, indicating potential upside for investors.
  • Recent product launches and updates, such as advancements in therapies for multiple myeloma and melanoma, position Bristol-Myers Squibb well in the competitive biopharmaceutical market.
  • With a strong focus on research and development, Bristol-Myers Squibb is likely to continue innovating, which can lead to new product approvals and increased market share.

Bristol-Myers Squibb
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Bristol-Myers Squibb for these reasons:

  • The payout ratio is currently negative, indicating that the company may not be returning profits to shareholders through dividends, which could be a concern for income-focused investors.
  • Some analysts have downgraded their price targets for Bristol-Myers Squibb, reflecting cautious sentiment about the company's near-term performance.
  • There are ongoing competitive pressures in the pharmaceutical industry, particularly in oncology, which could impact Bristol-Myers Squibb's market position and profitability.
  • With a significant number of analysts issuing hold ratings, there may be uncertainty regarding the stock's short-term performance, suggesting a lack of strong bullish sentiment.
  • Potential regulatory challenges and the need for continuous innovation in drug development could pose risks to the company's growth trajectory.

BMY Forecast - Frequently Asked Questions

According to the research reports of 22 Wall Street equities research analysts, the average twelve-month stock price forecast for Bristol-Myers Squibb is $58.00, with a high forecast of $73.00 and a low forecast of $39.00.

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last twelve months. There are currently 2 sell ratings, 13 hold ratings, 5 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BMY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BMY, but not buy additional shares or sell existing shares.

According to analysts, Bristol-Myers Squibb's stock has a predicted upside of 15.51% based on their 12-month stock forecasts.

Over the previous 90 days, Bristol-Myers Squibb's stock had 1 upgrade by analysts.

Bristol-Myers Squibb has been rated by research analysts at Argus, Cantor Fitzgerald, Jefferies Financial Group, Piper Sandler, The Goldman Sachs Group, UBS Group, Wells Fargo & Company, and William Blair in the past 90 days.

Analysts like Bristol-Myers Squibb less than other "medical" companies. The consensus rating for Bristol-Myers Squibb is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how BMY compares to other companies.


This page (NYSE:BMY) was last updated on 4/30/2025 by MarketBeat.com Staff
From Our Partners